SAT0239

PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS

Matthias Papo¹, Renato A. Sinico², Vitor Teixeira³, Maria-Letizia Urban⁴, Juliane Mahrhold⁵, Sara Monti⁶, Giulia Cassone⁷, Franco Schiavon⁸, Benjamin Seeliger⁹, Thomas Neumann¹⁰, Claus Kroegel¹¹, Matthieu Groh¹², Chiara Marvisi¹³, Maxime Samson¹⁴, Thomas Barba¹⁵, David Jayne³, Bernhard Hellmich⁵, Carlomaurizio Montecucco⁶, Carlo Salvarani⁷, Jean-Emmanuel Kahn¹², Bernard Bonnotte¹⁴, Cécile-Audrey Durel¹⁵, Luc Mouthon¹, Xavier Puéchal¹, Loïc Guillevin¹, Giacomo Emmi⁴, Augusto Vaglio¹³, Benjamin Terrier¹, French Vasculitis Study Group and EGPA European Collaborative Initiative. ¹Internal Medicine, Paris, France; ²Medicine and Surgery, Milan, Italy; ³Medicine, Cambridge, United Kingdom; ⁴Experimental and Clinical Medicine, Florence, Italy; ⁵Internal Medicine, Kirchheim, Germany; ⁶Rheumatology, Pavia, Italy; ⁷Rheumatology, Reggio Emilia and Modena, Italy; ⁸Rheumatology, Padova, Italy; ⁹Respiratory Medicine, Hannover, Germany; ¹⁰Rheumatology, St. Gallen, Switzerland; ¹¹Pneumology, Jena, Germany; ¹²Internal Medicine, Suresnes, France; ¹³Nephrology, Parma, Italy; ¹⁴Internal Medicine, Dijon, France; ¹⁵Internal Medicine, Lyon, France

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg-Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) control the disease, but GC-dependence is frequent. Evolving concepts distinguish vasculitis-related symptoms from asthma and/or ENT manifestations. That distinction has become even more important since the development of B-cell and eosinophil-targeted therapies.

Objectives: This study aimed to describe and identify characteristics predicting long-term EGPA outcomes.

Methods: We set up a multicenter European cohort that included 636 EGPA patients. Based on recent consensus, we distinguished 4 EGPA-evolutionary profiles: GC-dependent asthma and/or ENT manifestations (requiring prednisone >7.5 mg/d), ≥1 vasculitis relapse(s) (excluding asthma and/or ENT flares), both phenotypes, and complete remission (no GC-dependent asthma/ENT signs, no vasculitis relapse and prednisone <5 mg/d at last follow-up). Baseline and follow-up characteristics predicting those outcomes were analyzed.

Results: After median follow-up of 63 (IQR 30-110) months, 35.8% had GC-dependent asthma and/or ENT manifestations, 12.9% had ≥1 vasculitis relapse(s), 14.3% had both phenotypes, 14.6% were in complete remission, 14.4% were in partial remission and 7.8% had not reach remission.

Patients with GC-dependent asthma/ENT manifestations were younger at diagnosis ($p<0.0001$), had more frequent GC-treated asthma before overt EGPA ($p=0.002$), had more ENT manifestations ($p=0.01$) and less frequent MPO-ANCA ($p<0.0001$). Their daily GC dose was higher at every time point ($p<0.0001$), and they had more frequent active asthma at last follow-up ($p<0.0001$).

Patients with vasculitis relapse(s) had more frequently neurological manifestations at diagnosis ($p=0.002$) and MPO-ANCA positivity ($p<0.0001$), and less frequently pulmonary infiltrates ($p=0.031$). Median time from diagnosis-to-1st vasculitis relapse was 25 (11-60) months. During follow-up, their daily GC dose was lower than those with GC-dependent asthma/ENT manifestations, but similar to those in complete remission. At last follow-up, neurological sequelae tended to be more frequent ($p=0.06$).

Finally, patients in complete remission were older ($p<0.0001$), had more fever ($p=0.03$), less GC-treated asthma ($p=0.002$) and ENT manifestations at diagnosis ($p=0.01$), lower daily GC dose during follow-up ($p<0.0001$), lower eosinophils count at 6 months ($p=0.002$) and less frequent sequelae ($p=0.003$).

Conclusion: EGPA seems to evolve toward distinct phenotypic profiles, which could be identified using baseline and follow-up characteristics. Early identification of those profiles could allow guided choices of the best therapeutic option.

Disclosure of Interests: Matthias Papo: None declared, Renato A. Sinico: None declared, Vitor Teixeira: None declared, Maria-Letizia Urban: None declared, Juliane Mahrhold: None declared, Sara Monti: None declared, Giulia Cassone: None declared, Franco Schiavon: None declared, Benjamin Seeliger: None declared, Thomas Neumann: None declared, Claus Kroegel: None declared, Matthieu Groh: None declared, Chiara Marvisi: None declared, Maxime Samson: None declared, Thomas Barba: None declared, David Jayne Grant/research support from: David Jayne has received research grants from Chemocentryx, GSK, Roche/Genentech and Sanofi-Genzyme. He has received consultancy fees from Astra-Zeneca, Boehringer-Ingelheim, Chemocentryx, Chugai, GSK, Infla-RX, Insmad and Takeda, Bernhard Hellmich Consultant for: Roche, Speakers bureau: Abbvie, MSD, Roche, Novartis, Pfizer, Carlomaurizio Montecucco Speakers

bureau: AbbVie, Bristol-Myers Squibb, Celgene, Sanofi, Genzyme, Lilly, MSD, Pfizer, UCB, Carlo Salvarani Grant/research support from: Roche, Consultant for: Eli Lilly and Company, Roche, Abbvie, Jean-Emmanuel Kahn: None declared, Bernard Bonnotte: None declared, Cécile-Audrey Durel: None declared, Luc Mouthon: None declared, Xavier Puéchal: None declared, Loïc Guillevin: None declared, Giacomo Emmi: None declared, Augusto Vaglio: None declared, Benjamin Terrier: None declared

DOI: 10.1136/annrheumdis-2019-eular.4013

SAT0240

DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÇET'S SYNDROME OVERALL DAMAGE INDEX (BODI)

Matteo Piga¹, Alberto Floris¹, Gerard Espinosa², Nikolaos Kougkas³, Andrea Lo Monaco⁴, Giuseppe Lopalco⁵, Ida Orlando⁶, Vittorio Pirani⁷, Ernestina Santos^{8,9}, Luisa Serpa Pinto¹⁰, George Bertsias³, Luca Cantarini⁶, Alberto Cauli¹, Ricard Cervera², João Correia¹⁰, Marcello Govoni⁴, Florenzo Iannone⁵, Ana Martins Da Silva^{8,9}, Piergiorgio Neri¹¹, Carlos Vasconcelos⁹, Monica Muntoni¹², Alessandro Mathieu¹. ¹University of Cagliari, Rheumatology, Monserrato, Italy; ²University of Barcelona, Autoimmune Diseases, Barcelona, Catalonia, Spain; ³University of Crete, Rheumatology, Clinical Immunology and Allergy, Iraklion, Greece; ⁴University of Ferrara, Rheumatology, Ferrara, Italy; ⁵University of Bari, Rheumatology, Bari, Italy; ⁶University of Siena, Rheumatology, Siena, Italy; ⁷Università Politecnica delle Marche, Ophthalmology, Ancona, Italy; ⁸Centro Hospitalar do Porto/Hospital de Santo António, Neurology, Porto, Portugal; ⁹University of Porto, UMIB, Abel Salazar Biomedical Sciences Institute, Porto, Portugal; ¹⁰Hospital Santo Antonio Centro Hospitalar do Porto, Unidade de Imunologia Clínica, Porto, Portugal; ¹¹Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates; ¹²Patient delegate, Cagliari, Italy

Background: Irreversible organ damage is considered a core outcome by the OMERACT working group. However, no specific tools are currently available to detect and measure damage accrual in Behçet's syndrome (BS).

Objectives: To develop and preliminarily validate the Behçet's syndrome Overall Damage Index (BODI). NCT03803462.

Methods: A preliminary version of the instrument (p-BODI) was developed by reviewing pre-existing tools [e.g. Vasculitis damage index (VDI)] and through an extensive literature review. p-BODI was then reviewed and implemented by a multi-rounds Delphi process, involving an international and multidisciplinary (5 rheumatologists, 4 internist, 1 ophthalmologist, 1 neurologist) panel of experts in BS management and a patients' delegate. A group of clinicians (CG), not involved in the BODI development, was asked to independently score a set of clinical vignettes, in order to test the instrument reliability, after a training process consisting of a user manual and a video-tutorial. Then, Cohen's K and Intra-class correlation coefficient (ICC) between assessors and gold standard were calculated. Afterwards, BODI validation was conducted according to the OMERACT Filter 2.0 in a multicenter BS cohort.

Results: Starting from a list of 120 candidate items, the final version of BODI consisted of 4 overarching principles, 30 items and 12 sub-items (each of them scores one point) grouped in 8 domains (figure).

In terms of reliability, the mean K coefficient was 0.84 (95%CI 0.78 to 0.90) and the ICC was 0.88 (95%CI 0.80-0.95).

Validation cohort consisted of 228 BS patients (49.1% males), with a median (IQR) age and disease duration of 46.9 (35.5-55.0) and 11.7 (5.8-20.7) years, respectively. Overall, prevalence of any BODI damage (BODI ≥1) was 56.1% with a median score of 1.0 (0-2.0). In regard of construct validity, BODI score significantly correlated with VDI (Spearman's rho 0.693, $p<0.001$). Besides, BODI score did not correlate with BDAF (rho 0.016, $p=0.807$), contrary to VDI (rho 0.141, $p=0.034$). Such results support the validity of BODI, unlike VDI, in discriminating damage from current disease activity in BS. On multiple regression analysis, factors independently associated to higher BODI damage score were male gender (β coefficient 0.143; $p = 0.014$), longer disease duration (β 0.221; $p < 0.001$), past major organ involvement (β 0.377; $p < 0.001$) and required use of anti-TNF α inhibitors (β 0.222; $p < 0.001$).

Full agreement among the CG was reached in judging BODI as a credible, comprehensive, easy to use, timesaving and acceptable instrument.

Conclusion: BODI is the first tool specifically developed to assess damage in BS. Preliminary data encourage further validation of BODI in more extended and multi-ethnic BS cohorts before being applied in clinical practice and as a therapeutic outcome.